177Lu-PSMA-VG-01 / Vitsgen Therapeutics - LARVOL DELTA

Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC） (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: VitsGen Therapeutics Inc.

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

[177Lu]Lu-VG-PSMA-01 Exhibits High Theranostic Potential for the Treatment of Metastatic Castration-Resistant Prostate Cancer (SNMMI 2025) - "In vitro, compared to [177Lu]Lu-PSMA-617, the findings showed that [177Lu]Lu-VG-PSMA-01 had higher internalization in tumor cells. Imaging of [177Lu]Lu-VG-PSMA-01 in LNCaP bearing mice showed high tumor uptake and tumor retention (21.1 % ID/g at 4 h p.i.; 33.6% ID/g at 8 h p.i.; 18.8% ID/g at 24 h p.i.; and 14.3% ID/g at 72 h p.i.). Importantly, biodistribution data demonstrated that there was no clinically meaningful bone marrow activity."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

[177Lu]Lu-VG-PSMA-01 Exhibits High Theranostic Potential for the Treatment of Metastatic Castration-Resistant Prostate Cancer (SNMMI 2025) - "In vitro, compared to [177Lu]Lu-PSMA-617, the findings showed that [177Lu]Lu-VG-PSMA-01 had higher internalization in tumor cells. Imaging of [177Lu]Lu-VG-PSMA-01 in LNCaP bearing mice showed high tumor uptake and tumor retention (21.1 % ID/g at 4 h p.i.; 33.6% ID/g at 8 h p.i.; 18.8% ID/g at 24 h p.i.; and 14.3% ID/g at 72 h p.i.). Importantly, biodistribution data demonstrated that there was no clinically meaningful bone marrow activity."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor